Status: Recruiting
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.
Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: Perspective TherapeuticsUpdated: Jun 10, 2026Locations: 13
Eligibility criteria
Ability to understand and willingness to provide informed consent, willingness t... [+12]
Active secondary malignancy [+16]